Supernus Pharmaceuticals and Indivior Pharmaceuticals have merged to form Supernus, Inc., a diversified biopharmaceutical company focused on central nervous system (CNS) diseases. The combined company has an 11-product portfolio covering opioid use disorder, psychiatry, and neurology, with five core growth drivers. This merger enhances financial flexibility, cash flow, and scale, enabling investment in growth products and pipeline advancement. Supernus, Inc. will trade on Nasdaq under the ticker SUPN starting November 3, 2026, with leadership from Supernus' CEO Jack Khattar and a balanced board from both legacy companies.
Supernus and Indivior's merger to form Supernus, Inc. is noted here with Pluang's health sector market data as of Nov 02, 2026 21:12 WIB. Among 150 priced health-sector US stocks tradable on Pluang, 104 rose and 33 fell today. Notable movers include Adaptive Biotechnologies Corp (ADPT) at USD 27.36 with a 2.78% increase, BioNano Genomics Inc (BNGO) at USD 1.18 up 2.61%, and Aurora Cannabis Inc (ACB) at USD 4.17 rising 2.46%.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
